Reata Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Reata Pharmaceuticals (RETA) IPO Opens Flat
May 26, 2016 10:39 AM EDTToday's IPO for Reata Pharmaceuticals, Inc. (Nasdaq: RETA) opened for trading at $11.06 after pricing 5,500,000 shares of its Class A common stock at $11.00 per share. The company was recently looking to offer 4 million shares and expected a pricing range of $14 - $16 per... More
